DeepMed Research

Itraconazole

Generic Name: Itraconazole

Brand Names: Sporanox, Tolsura

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₃₈Cl_₂N_₈O_₄

CAS Number: 84625-61-6

Unique Ingredient Identifier: 304NUG5GF4

Background: One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication: For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions: Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases

Clinical Trials

Itraconazole in Advanced Ovarian Cancer

Not Applicable

Not yet recruiting

Conditions: Ovarian Carcinoma

Interventions: Drug: Itraconazole capsule
Drug: Placebo

First Posted Date: 2022-10-24

Last Posted Date: 2022-10-24

Lead Sponsor: Tanta University

Target Recruit Count: 66

Registration Number: NCT05591560

Locations: 🇪🇬
Tanta University, Faculty of Pharmacy, Tanta, Egypt

Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis

Phase 1

Completed

Conditions: Onychomycosis

Interventions: Drug: itraconazole
Drug: terbinafine

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-19

Lead Sponsor: Combined Military Hospital Abbottabad

Target Recruit Count: 100

Registration Number: NCT05578950

Locations: 🇵🇰
Cmh Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies

Interventions: Drug: AZD5305
Drug: Itraconazole

First Posted Date: 2022-10-10

Last Posted Date: 2024-06-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT05573724

Locations: 🇷🇴
Research Site, Cluj-Napoca, Romania

A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510
Drug: Itraconazole

First Posted Date: 2022-10-05

Last Posted Date: 2025-03-05

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT05568082

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States

Comparative Study Between Pulsed and Continuous Itraconazole for the Treatment of Onychomycosis

Phase 1

Completed

Conditions: Onychomychosis

Interventions: Drug: Itraconazole

First Posted Date: 2022-10-05

Last Posted Date: 2022-10-05

Lead Sponsor: Combined Military Hospital Abbottabad

Target Recruit Count: 60

Registration Number: NCT05567484

Locations: 🇵🇰
cmh Abbottabad, Abbottabad, Khyber Pakhtunkhwa, Pakistan

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Phase 2

Recruiting

Conditions: Esophageal Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Gastroesophageal Junction Carcinoma

Interventions: Drug: Itraconazole

First Posted Date: 2022-10-03

Last Posted Date: 2024-11-21

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 78

Registration Number: NCT05563766

Locations: 🇺🇸
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States
🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States
🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

and more 4 locations

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Camizestrant
Drug: Itraconazole

First Posted Date: 2022-09-23

Last Posted Date: 2023-01-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT05551897

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-1004-1239 (10 mg)
Drug: Itraconazole (200 mg, o.d.)

First Posted Date: 2022-09-22

Last Posted Date: 2022-11-08

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 16

Registration Number: NCT05549531

Locations: 🇵🇹
BlueClinical Phase 1, Porto, Portugal

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: vepdegestrant
Drug: Itraconazole

First Posted Date: 2022-09-13

Last Posted Date: 2023-06-23

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05538312

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-708
Drug: Placebo
Drug: Midazolam
Drug: Itraconazole

First Posted Date: 2022-08-29

Last Posted Date: 2023-03-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 64

Registration Number: NCT05518734

Locations: 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy